<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068730</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-120</org_study_id>
    <nct_id>NCT01068730</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects</brief_title>
  <official_title>Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets Manufactured by Bristol-Myers Squibb Relative to 500 mg and 1000 mg Diabex (Metformin) Tablets Marketed in Australia by Alphapharm Administered to Healthy Subjects in the Fed State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the bioequivalence of 500 mg and 1000 mg Glucophage tablets manufactured by
      BMS relative to the respective strengths of 500 mg and 1000 mg Diabex tablets marketed in
      Australia by Alphapharm in the fed state
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</measure>
    <time_frame>AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE</measure>
    <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Abnormal Physical Findings</measure>
    <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
    <description>Physical findings that were considered abnormal by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Abnormal Vital Sign Findings Reported as an AE</measure>
    <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
    <description>per investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology</measure>
    <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>Clinically significant was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry</measure>
    <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>Clinically significant was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis</measure>
    <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
    <description>Clinically significant was determined by the investigator.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma</description>
  </other_outcome>
  <other_outcome>
    <measure>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</measure>
    <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
    <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Diabex)</intervention_name>
    <description>Tablets, Oral, 500 mg, Once daily, single dose</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Diabex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage™)</intervention_name>
    <description>Tablets, Oral, 500 mg, Once Daily, single dose</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Glucophage™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Glucophage™)</intervention_name>
    <description>Tablets, Oral, 1000 mg, Once daily, single dose</description>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Glucophage™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin (Diabex)</intervention_name>
    <description>Tablets, Oral, 1000 mg, Once daily, single dose</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Diabex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18 to 55 inclusive

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, electrocardiograms (ECGs), and clinical
             laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent (within 3 months) gastrointestinal disease

          -  Any major surgery within 4 weeks of study drug administration

          -  History of allergy or intolerance to metformin or other similar acting agents

          -  Prior exposure to metformin within 3 months of study drug administration

          -  Estimated creatinine clearance (Clcr) of &lt; 80ml/min using the Cockcroft Gault formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <results_first_submitted>January 20, 2012</results_first_submitted>
  <results_first_submitted_qc>February 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2012</results_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 28 participants who met all of the inclusion and none of the exclusion criteria were planned and enrolled in the study from a single site in the United States.</recruitment_details>
      <pre_assignment_details>Participants were screened for eligibility within 21 days before Day 1 of period 1. On Day −1 of each period, the participants were admitted to the clinical facility and confined for 4 days. All the 28 participants were randomly assigned to 1 of 4 treatment sequences (ADBC, BACD, CBDA, or DCAB). The washout between each dose was at least 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ADBC</title>
          <description>Treatment A (period 1): single oral 500-mg Diabex (metformin) tablet administered under fed condition. Treatment D (period 2): single oral 1000-mg Glucophage (metformin) tablet administered under fed condition. Treatment B (period 3): single oral 500-mg Glucophage tablet administered under fed condition. Treatment C (period 4): single oral 1000-mg Diabex tablet administered under fed condition.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence BACD</title>
          <description>Treatment B (period 1): single oral 500-mg Glucophage tablet administered under fed condition. Treatment A (period 2): single oral 500-mg Diabex tablet administered under fed condition. Treatment C (period 3): single oral 1000-mg Diabex tablet administered under fed condition. Treatment D (period 4): single oral 1000-mg Glucophage tablet administered under fed condition.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence CBDA</title>
          <description>Treatment C (period 1): single oral 1000-mg Diabex tablet administered under fed condition. Treatment B (period 2): single oral 500-mg Glucophage tablet administered under fed condition. Treatment D (period 3): single oral 1000-mg Glucophage tablet administered under fed condition. Treatment A (period 4): single oral 500-mg Diabex tablet administered under fed condition.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence DCAB</title>
          <description>Treatment D (period 1): single oral 1000-mg Glucophage tablet administered under fed condition. Treatment C (period 2): single oral 1000-mg Diabex tablet administered under fed condition. Treatment A (period 3): single oral 500-mg Diabex tablet administered under fed condition. Treatment B (period 4): single oral 500-mg Glucophage tablet administered under fed condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Personal reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Family emergency</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled and Treated Participants</title>
          <description>Participants who were randomly assigned to 1 of 4 treatment sequences (ADBC, BACD, CBDA, or DCAB). Treatment A: single oral 500-mg Diabex (metformin) tablet administered under fed condition. Treatment B: single oral 500-mg Glucophage tablet administered under fed condition. Treatment C: single oral 1000-mg Diabex tablet administered under fed condition.Treatment D: single oral 1000-mg Glucophage (metformin) tablet administered under fed condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="11.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.54" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.02" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.58" spread="3.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants with evaluable PK analyses. In treatment D, AUC (0-inf) was not analysed for 1 participant who did not have a clear terminal elimination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single Oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single Oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single Oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single Oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.</description>
          <population>All treated participants with evaluable PK analyses. In treatment D, AUC (0-inf) was not analysed for 1 participant who did not have a clear terminal elimination phase.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7062.76" spread="26.91"/>
                    <measurement group_id="O2" value="7187.14" spread="25.95"/>
                    <measurement group_id="O3" value="11577.85" spread="27.36"/>
                    <measurement group_id="O4" value="11424.73" spread="29.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the 500-mg or 1000-mg Glucophage tablets manufactured by BMS and 500-mg or 1000-mg Diabex tablets manufactured in Australia by Alphapharm, then 20 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would have provided 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) and (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>102.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.07</ci_lower_limit>
            <ci_upper_limit>106.23</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares (LS) means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the 500-mg or 1000-mg Glucophage tablets manufactured by BMS and 500-mg or 1000-mg Diabex tablets manufactured in Australia by Alphapharm, then 20 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would have provided 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) and (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>99.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.16</ci_lower_limit>
            <ci_upper_limit>103.31</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric LS means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>7062.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>7245.2</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>11680</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)]</param_type>
            <param_value>11641</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants with evaluable PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single Oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single Oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single Oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single Oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin PK Parameter Observed Maximum Plasma Concentration (Cmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.</description>
          <population>All treated participants with evaluable PK analyses.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1013.57" spread="25.67"/>
                    <measurement group_id="O2" value="1019.59" spread="25.26"/>
                    <measurement group_id="O3" value="1635.30" spread="27.67"/>
                    <measurement group_id="O4" value="1593.20" spread="26.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the 500-mg or 1000-mg Glucophage tablets manufactured by BMS and 500-mg or 1000-mg Diabex tablets manufactured in Australia by Alphapharm, then 20 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would have provided 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) and (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>101.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.36</ci_lower_limit>
            <ci_upper_limit>106.11</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the 500-mg or 1000-mg Glucophage tablets manufactured by BMS and 500-mg or 1000-mg Diabex tablets manufactured in Australia by Alphapharm, then 20 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 20 subjects would have provided 97% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence was concluded if the 90% confidence intervals (CIs) for the test-to-reference ratios (B/A) and (D/C) of geometric means were entirely contained within 80% to 125% for both Cmax and AUC0-inf.</non_inferiority_desc>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>98.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.94</ci_lower_limit>
            <ci_upper_limit>103.59</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>1013.6</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>1024.9</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>1643.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng/mL)</param_type>
            <param_value>1621.6</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
        <time_frame>AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single Oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single Oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single Oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single Oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants With atleast 1 Treatment-emergent AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations Due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE</title>
        <description>Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.</description>
        <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single Oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single Oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single Oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single Oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Electrocardiogram Abnormalities Considered Clinically Significant or Reported as an AE</title>
          <description>Clinically significant was determined by the investigator. ECGs were recorded after participants had been supine for at least 5 minutes.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Abnormal Physical Findings</title>
        <description>Physical findings that were considered abnormal by the investigator.</description>
        <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Abnormal Physical Findings</title>
          <description>Physical findings that were considered abnormal by the investigator.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Abnormal Vital Sign Findings Reported as an AE</title>
        <description>per investigator</description>
        <time_frame>From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Abnormal Vital Sign Findings Reported as an AE</title>
          <description>per investigator</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants with evaluable PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Pharmacokinetic (PK) Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.</description>
          <population>All treated participants with evaluable PK analyses.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.79"/>
                    <measurement group_id="O2" value="3.56" spread="0.80"/>
                    <measurement group_id="O3" value="3.22" spread="0.64"/>
                    <measurement group_id="O4" value="3.23" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants with evaluable PK analyses. In treatment D, T 1/2 was not analysed for 1 participant who did not have a clear terminal elimination phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Pharmacokinetic (PK) Parameter Terminal Half-life (T 1/2)</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma</description>
          <population>All treated participants with evaluable PK analyses. In treatment D, T 1/2 was not analysed for 1 participant who did not have a clear terminal elimination phase.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2310" spread="5.3180"/>
                    <measurement group_id="O2" value="11.5349" spread="3.7633"/>
                    <measurement group_id="O3" value="12.6152" spread="4.2032"/>
                    <measurement group_id="O4" value="12.5268" spread="4.3137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology</title>
        <description>Clinically significant was determined by the investigator.</description>
        <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Hematology</title>
          <description>Clinically significant was determined by the investigator.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry</title>
        <description>Clinically significant was determined by the investigator.</description>
        <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Serum Chemistry</title>
          <description>Clinically significant was determined by the investigator.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis</title>
        <description>Clinically significant was determined by the investigator.</description>
        <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
        <population>All treated participants not discontinuing prior to the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>1000 mg metformin (Diabex): Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>1000 mg metformin (Glucophage™): Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Clinical Laboratory Findings Considered Clinically Significant or Reported as an AE: Urinalysis</title>
          <description>Clinically significant was determined by the investigator.</description>
          <population>All treated participants not discontinuing prior to the end of the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
        <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
        <time_frame>Periods 1, 2, 3, &amp; 4: pre-dosing, 15, 30, 45 mins &amp; 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 &amp; 48 hrs post-dosing</time_frame>
        <population>All treated participants with evaluable PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - 500 mg Diabex</title>
            <description>500 mg metformin (Diabex): Single oral dose of 500 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - 500 mg Glucophage</title>
            <description>500 mg metformin (Glucophage™): Single oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - 1000 mg Diabex</title>
            <description>Single oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
          </group>
          <group group_id="O4">
            <title>Treatment D - 1000 mg Glucophage</title>
            <description>Single oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
          <description>PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC[0-t] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.</description>
          <population>All treated participants with evaluable PK analyses.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6907.06" spread="27.16"/>
                    <measurement group_id="O2" value="7078.70" spread="26.18"/>
                    <measurement group_id="O3" value="11305.27" spread="27.77"/>
                    <measurement group_id="O4" value="11129.89" spread="28.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>103.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.75</ci_lower_limit>
            <ci_upper_limit>106.75</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric LS means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (%) of Geometric LS Means</param_type>
            <param_value>99.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.08</ci_lower_limit>
            <ci_upper_limit>102.92</ci_upper_limit>
            <estimate_desc>Ratio=Treatment D/Treatment C. Geometric LS means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>6907.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>7127.4</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>11391</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for Treatment D</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>[Geometric Least Squares Mean (ng*hr/mL)</param_type>
            <param_value>11327</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study drug administration Day 1/Period 1 till study discharge. Duration of the study was approximately 45 days (including screening).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment C - 1000 mg Diabex</title>
          <description>1000 mg metformin (Diabex): Single Oral dose of 1000 mg Diabex tablet administered in the fed condition</description>
        </group>
        <group group_id="E2">
          <title>Treatment D - 1000 mg Glucophage</title>
          <description>1000 mg metformin (Glucophage™): Single Oral dose of 1000 mg Glucophage tablet administered in the fed condition</description>
        </group>
        <group group_id="E3">
          <title>Treatment A - 500 mg Diabex</title>
          <description>500 mg metformin (Diabex): Single Oral dose of 500 mg Diabex tablet administered in the fed condition</description>
        </group>
        <group group_id="E4">
          <title>Treatment B - 500 mg Glucophage</title>
          <description>500 mg metformin (Glucophage™): Single Oral dose of 500 mg Glucophage tablet administered in the fed condition</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

